ilShinbiobase일신바이오
068330 · KOSDAQ · ₩068330 · 일신바이오
₩1,000▲ ₩6 (0.60%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩15B | ₩11B | ₩16B | ₩20B | ₩24B |
| Cost of sales | ₩6.8B | ₩4.5B | ₩7B | ₩9.9B | ₩12B |
| Gross profit | ₩7.7B | ₩6.3B | ₩9.4B | ₩11B | ₩13B |
| Operating income | ₩4.5B | ₩2.3B | ₩6.2B | ₩5.1B | ₩7.3B |
| Net income | ₩4.8B | ₩3.8B | ₩6.2B | ₩3.8B | ₩5.9B |
| Net income to shareholders | ₩4.8B | ₩3.8B | ₩6.2B | ₩3.8B | ₩5.9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩69B | ₩64B | ₩61B | ₩58B | ₩56B |
| Current assets | ₩55B | ₩50B | ₩47B | ₩41B | ₩38B |
| Cash and equivalents | ₩2B | ₩1.7B | ₩3.2B | ₩5.7B | ₩11B |
| Total liabilities | ₩3.8B | ₩3.5B | ₩3.6B | ₩4.6B | ₩6.4B |
| Current liabilities | ₩3.7B | ₩3.5B | ₩3.4B | ₩4.4B | ₩6B |
| Borrowings | — | — | — | ₩1.5B | ₩1.9B |
| Total equity | ₩65B | ₩60B | ₩57B | ₩54B | ₩50B |
| Shareholders' equity | ₩65B | ₩60B | ₩57B | ₩54B | ₩50B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩5.3B | ₩4.1B | ₩5.9B | ₩2.6B | ₩6.7B |
| Capital spending | ₩5.3M | — | ₩262M | ₩93M | ₩139M |
| Free cash flow | ₩5.3B | ₩4.1B | ₩5.7B | ₩2.6B | ₩6.6B |
| Dividends paid | ₩292M | ₩292M | ₩300M | ₩300M | ₩300M |
Consolidated where available. Amounts in won.
Also known as: ilShinbiobase / 일신바이오 / 068330 / KRX:068330
Source: KRX statistical information